← Back to search

Protein Structures and Oligomeric States

Enter a protein name, UniProt accession or PDB ID. Name searches ask you to confirm the protein identity before related structures are queried.

Current Protein Identity：Q82122 New Search
13PDB entries
66Biological assembly
222chain/assembly records
Main Difference Dimensions in This Set
Different construct Different mutation/modification Different assembly state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics

Difference tags compare only the current result set; every original PDB and assembly record remains separate.

Related-Structure Differences

Each row represents one biological assembly in one PDB entry; multiple monomers of the same protein are listed separately.

PDB Entry Assembly / Oligomeric State Construct Mutations and Modifications Ligands, Ions and Non-polymers Experimental Method Experimental Conditions Structure Quality
1AYM HUMAN RHINOVIRUS 16 COAT PROTEIN AT HIGH RESOLUTION Deposited 1997-11-06 Assembly 1 Protein heterocomplex Heteromer；Protein × 240 PDB declaration: 240-MERIC（240） Consistent with protein count
Chain 1 568–852（285 aa）
Chain 2 69–329（261 aa）
Chain 3 330–567（238 aa）
Mutation：N-TERMINAL MYRISTOYLATION ON VP4 Mutation：N-TERMINAL MYRISTOYLATION ON VP4 Mutation：N-TERMINAL MYRISTOYLATION ON VP4 ZN ZINC ION × 60 DAO LAURIC ACID × 60 MYR MYRISTIC ACID × 60 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；pH 7.5
Resolution 2.15 Å R-free 0.233
1AYM HUMAN RHINOVIRUS 16 COAT PROTEIN AT HIGH RESOLUTION Deposited 1997-11-06 Assembly 2 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric（4） Consistent with protein count
Chain 1 568–852（285 aa）
Chain 2 69–329（261 aa）
Chain 3 330–567（238 aa）
Mutation：N-TERMINAL MYRISTOYLATION ON VP4 Mutation：N-TERMINAL MYRISTOYLATION ON VP4 Mutation：N-TERMINAL MYRISTOYLATION ON VP4 ZN ZINC ION × 1 DAO LAURIC ACID × 1 MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；pH 7.5
Resolution 2.15 Å R-free 0.233
1AYM HUMAN RHINOVIRUS 16 COAT PROTEIN AT HIGH RESOLUTION Deposited 1997-11-06 Assembly 3 Protein heterocomplex Heteromer；Protein × 20 PDB declaration: eicosameric（20） Consistent with protein count
Chain 1 568–852（285 aa）
Chain 2 69–329（261 aa）
Chain 3 330–567（238 aa）
Mutation：N-TERMINAL MYRISTOYLATION ON VP4 Mutation：N-TERMINAL MYRISTOYLATION ON VP4 Mutation：N-TERMINAL MYRISTOYLATION ON VP4 ZN ZINC ION × 5 DAO LAURIC ACID × 5 MYR MYRISTIC ACID × 5 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；pH 7.5
Resolution 2.15 Å R-free 0.233
1AYM HUMAN RHINOVIRUS 16 COAT PROTEIN AT HIGH RESOLUTION Deposited 1997-11-06 Assembly 4 Protein heterocomplex Heteromer；Protein × 24 PDB declaration: 24-meric（24） Consistent with protein count
Chain 1 568–852（285 aa）
Chain 2 69–329（261 aa）
Chain 3 330–567（238 aa）
Mutation：N-TERMINAL MYRISTOYLATION ON VP4 Mutation：N-TERMINAL MYRISTOYLATION ON VP4 Mutation：N-TERMINAL MYRISTOYLATION ON VP4 ZN ZINC ION × 6 DAO LAURIC ACID × 6 MYR MYRISTIC ACID × 6 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；pH 7.5
Resolution 2.15 Å R-free 0.233
1AYM HUMAN RHINOVIRUS 16 COAT PROTEIN AT HIGH RESOLUTION Deposited 1997-11-06 Assembly 5 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric（4） Consistent with protein count
Chain 1 568–852（285 aa）
Chain 2 69–329（261 aa）
Chain 3 330–567（238 aa）
Mutation：N-TERMINAL MYRISTOYLATION ON VP4 Mutation：N-TERMINAL MYRISTOYLATION ON VP4 Mutation：N-TERMINAL MYRISTOYLATION ON VP4 ZN ZINC ION × 1 DAO LAURIC ACID × 1 MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；pH 7.5
Resolution 2.15 Å R-free 0.233
1AYM HUMAN RHINOVIRUS 16 COAT PROTEIN AT HIGH RESOLUTION Deposited 1997-11-06 Assembly 6 Protein heterocomplex Heteromer；Protein × 120 PDB declaration: 120-meric（120） Consistent with protein count
Chain 1 568–852（285 aa）
Chain 2 69–329（261 aa）
Chain 3 330–567（238 aa）
Mutation：N-TERMINAL MYRISTOYLATION ON VP4 Mutation：N-TERMINAL MYRISTOYLATION ON VP4 Mutation：N-TERMINAL MYRISTOYLATION ON VP4 ZN ZINC ION × 30 DAO LAURIC ACID × 30 MYR MYRISTIC ACID × 30 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；pH 7.5
Resolution 2.15 Å R-free 0.233
1AYN HUMAN RHINOVIRUS 16 COAT PROTEIN Deposited 1997-11-06 Assembly 1 Protein heterocomplex Heteromer；Protein × 240 PDB declaration: 240-MERIC（240） Consistent with protein count
Chain 1 568–852（285 aa）
Chain 2 69–329（261 aa）
Chain 3 330–567（238 aa）
Mutation：N-TERMINAL MYRISTOYLATION ON VP4 Mutation：N-TERMINAL MYRISTOYLATION ON VP4 Mutation：N-TERMINAL MYRISTOYLATION ON VP4 ZN ZINC ION × 60 DAO LAURIC ACID × 60 MYR MYRISTIC ACID × 60 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；VIRUS WAS CRYSTALLISED USING THE HANGING DROP METHOD. 5 MICROLITERS OF VIRUS SOLUTION IN 0.25M HEPES BUFFER (PH 7.5), WITH 0.25M NACL WAS MIXED WITH 5 MICROLITERS OF THE RESERVOIR SOLUTION, 0.5-1.5% PEG 8000., vapor diffusion - hanging drop
Resolution 2.90 Å R-free 0.230
1AYN HUMAN RHINOVIRUS 16 COAT PROTEIN Deposited 1997-11-06 Assembly 2 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric（4） Consistent with protein count
Chain 1 568–852（285 aa）
Chain 2 69–329（261 aa）
Chain 3 330–567（238 aa）
Mutation：N-TERMINAL MYRISTOYLATION ON VP4 Mutation：N-TERMINAL MYRISTOYLATION ON VP4 Mutation：N-TERMINAL MYRISTOYLATION ON VP4 ZN ZINC ION × 1 DAO LAURIC ACID × 1 MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；VIRUS WAS CRYSTALLISED USING THE HANGING DROP METHOD. 5 MICROLITERS OF VIRUS SOLUTION IN 0.25M HEPES BUFFER (PH 7.5), WITH 0.25M NACL WAS MIXED WITH 5 MICROLITERS OF THE RESERVOIR SOLUTION, 0.5-1.5% PEG 8000., vapor diffusion - hanging drop
Resolution 2.90 Å R-free 0.230
1AYN HUMAN RHINOVIRUS 16 COAT PROTEIN Deposited 1997-11-06 Assembly 3 Protein heterocomplex Heteromer；Protein × 20 PDB declaration: eicosameric（20） Consistent with protein count
Chain 1 568–852（285 aa）
Chain 2 69–329（261 aa）
Chain 3 330–567（238 aa）
Mutation：N-TERMINAL MYRISTOYLATION ON VP4 Mutation：N-TERMINAL MYRISTOYLATION ON VP4 Mutation：N-TERMINAL MYRISTOYLATION ON VP4 ZN ZINC ION × 5 DAO LAURIC ACID × 5 MYR MYRISTIC ACID × 5 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；VIRUS WAS CRYSTALLISED USING THE HANGING DROP METHOD. 5 MICROLITERS OF VIRUS SOLUTION IN 0.25M HEPES BUFFER (PH 7.5), WITH 0.25M NACL WAS MIXED WITH 5 MICROLITERS OF THE RESERVOIR SOLUTION, 0.5-1.5% PEG 8000., vapor diffusion - hanging drop
Resolution 2.90 Å R-free 0.230
1AYN HUMAN RHINOVIRUS 16 COAT PROTEIN Deposited 1997-11-06 Assembly 4 Protein heterocomplex Heteromer；Protein × 24 PDB declaration: 24-meric（24） Consistent with protein count
Chain 1 568–852（285 aa）
Chain 2 69–329（261 aa）
Chain 3 330–567（238 aa）
Mutation：N-TERMINAL MYRISTOYLATION ON VP4 Mutation：N-TERMINAL MYRISTOYLATION ON VP4 Mutation：N-TERMINAL MYRISTOYLATION ON VP4 ZN ZINC ION × 6 DAO LAURIC ACID × 6 MYR MYRISTIC ACID × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；VIRUS WAS CRYSTALLISED USING THE HANGING DROP METHOD. 5 MICROLITERS OF VIRUS SOLUTION IN 0.25M HEPES BUFFER (PH 7.5), WITH 0.25M NACL WAS MIXED WITH 5 MICROLITERS OF THE RESERVOIR SOLUTION, 0.5-1.5% PEG 8000., vapor diffusion - hanging drop
Resolution 2.90 Å R-free 0.230
1AYN HUMAN RHINOVIRUS 16 COAT PROTEIN Deposited 1997-11-06 Assembly 5 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric（4） Consistent with protein count
Chain 1 568–852（285 aa）
Chain 2 69–329（261 aa）
Chain 3 330–567（238 aa）
Mutation：N-TERMINAL MYRISTOYLATION ON VP4 Mutation：N-TERMINAL MYRISTOYLATION ON VP4 Mutation：N-TERMINAL MYRISTOYLATION ON VP4 ZN ZINC ION × 1 DAO LAURIC ACID × 1 MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；VIRUS WAS CRYSTALLISED USING THE HANGING DROP METHOD. 5 MICROLITERS OF VIRUS SOLUTION IN 0.25M HEPES BUFFER (PH 7.5), WITH 0.25M NACL WAS MIXED WITH 5 MICROLITERS OF THE RESERVOIR SOLUTION, 0.5-1.5% PEG 8000., vapor diffusion - hanging drop
Resolution 2.90 Å R-free 0.230
1AYN HUMAN RHINOVIRUS 16 COAT PROTEIN Deposited 1997-11-06 Assembly 6 Protein heterocomplex Heteromer；Protein × 120 PDB declaration: 120-meric（120） Consistent with protein count
Chain 1 568–852（285 aa）
Chain 2 69–329（261 aa）
Chain 3 330–567（238 aa）
Mutation：N-TERMINAL MYRISTOYLATION ON VP4 Mutation：N-TERMINAL MYRISTOYLATION ON VP4 Mutation：N-TERMINAL MYRISTOYLATION ON VP4 ZN ZINC ION × 30 DAO LAURIC ACID × 30 MYR MYRISTIC ACID × 30 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；VIRUS WAS CRYSTALLISED USING THE HANGING DROP METHOD. 5 MICROLITERS OF VIRUS SOLUTION IN 0.25M HEPES BUFFER (PH 7.5), WITH 0.25M NACL WAS MIXED WITH 5 MICROLITERS OF THE RESERVOIR SOLUTION, 0.5-1.5% PEG 8000., vapor diffusion - hanging drop
Resolution 2.90 Å R-free 0.230
1C8M REFINED CRYSTAL STRUCTURE OF HUMAN RHINOVIRUS 16 COMPLEXED WITH VP63843 (PLECONARIL), AN ANTI-PICORNAVIRAL DRUG CURRENTLY IN CLINICAL TRIALS Deposited 2000-05-26 Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC（240） Consistent with protein count
Chain 1 568–852（285 aa） Fragment：RESIDUES 569-853
Chain 2 78–329（252 aa） Fragment：RESIDUES 79-330
Chain 3 330–567（238 aa） Fragment：RESIDUES 331-568
Chain 4 1–77（77 aa） Fragment：RESIDUES 2-78
Not recorded ZN ZINC ION × 60 W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 60 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；PEG8000, HEPES BUFFER, SODIUM CHLORIDE, CALCIUM CHLORIDE, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.80 Å R-free 0.226
1C8M REFINED CRYSTAL STRUCTURE OF HUMAN RHINOVIRUS 16 COMPLEXED WITH VP63843 (PLECONARIL), AN ANTI-PICORNAVIRAL DRUG CURRENTLY IN CLINICAL TRIALS Deposited 2000-05-26 Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric（4） Consistent with protein count
Chain 1 568–852（285 aa） Fragment：RESIDUES 569-853
Chain 2 78–329（252 aa） Fragment：RESIDUES 79-330
Chain 3 330–567（238 aa） Fragment：RESIDUES 331-568
Chain 4 1–77（77 aa） Fragment：RESIDUES 2-78
Not recorded ZN ZINC ION × 1 W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；PEG8000, HEPES BUFFER, SODIUM CHLORIDE, CALCIUM CHLORIDE, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.80 Å R-free 0.226
1C8M REFINED CRYSTAL STRUCTURE OF HUMAN RHINOVIRUS 16 COMPLEXED WITH VP63843 (PLECONARIL), AN ANTI-PICORNAVIRAL DRUG CURRENTLY IN CLINICAL TRIALS Deposited 2000-05-26 Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric（20） Consistent with protein count
Chain 1 568–852（285 aa） Fragment：RESIDUES 569-853
Chain 2 78–329（252 aa） Fragment：RESIDUES 79-330
Chain 3 330–567（238 aa） Fragment：RESIDUES 331-568
Chain 4 1–77（77 aa） Fragment：RESIDUES 2-78
Not recorded ZN ZINC ION × 5 W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 5 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；PEG8000, HEPES BUFFER, SODIUM CHLORIDE, CALCIUM CHLORIDE, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.80 Å R-free 0.226
1C8M REFINED CRYSTAL STRUCTURE OF HUMAN RHINOVIRUS 16 COMPLEXED WITH VP63843 (PLECONARIL), AN ANTI-PICORNAVIRAL DRUG CURRENTLY IN CLINICAL TRIALS Deposited 2000-05-26 Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric（24） Consistent with protein count
Chain 1 568–852（285 aa） Fragment：RESIDUES 569-853
Chain 2 78–329（252 aa） Fragment：RESIDUES 79-330
Chain 3 330–567（238 aa） Fragment：RESIDUES 331-568
Chain 4 1–77（77 aa） Fragment：RESIDUES 2-78
Not recorded ZN ZINC ION × 6 W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；PEG8000, HEPES BUFFER, SODIUM CHLORIDE, CALCIUM CHLORIDE, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.80 Å R-free 0.226
1C8M REFINED CRYSTAL STRUCTURE OF HUMAN RHINOVIRUS 16 COMPLEXED WITH VP63843 (PLECONARIL), AN ANTI-PICORNAVIRAL DRUG CURRENTLY IN CLINICAL TRIALS Deposited 2000-05-26 Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric（4） Consistent with protein count
Chain 1 568–852（285 aa） Fragment：RESIDUES 569-853
Chain 2 78–329（252 aa） Fragment：RESIDUES 79-330
Chain 3 330–567（238 aa） Fragment：RESIDUES 331-568
Chain 4 1–77（77 aa） Fragment：RESIDUES 2-78
Not recorded ZN ZINC ION × 1 W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；PEG8000, HEPES BUFFER, SODIUM CHLORIDE, CALCIUM CHLORIDE, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.80 Å R-free 0.226
1C8M REFINED CRYSTAL STRUCTURE OF HUMAN RHINOVIRUS 16 COMPLEXED WITH VP63843 (PLECONARIL), AN ANTI-PICORNAVIRAL DRUG CURRENTLY IN CLINICAL TRIALS Deposited 2000-05-26 Assembly 6 Protein homooligomer Homooligomer；Protein × 120 PDB declaration: 120-meric（120） Consistent with protein count
Chain 1 568–852（285 aa） Fragment：RESIDUES 569-853
Chain 2 78–329（252 aa） Fragment：RESIDUES 79-330
Chain 3 330–567（238 aa） Fragment：RESIDUES 331-568
Chain 4 1–77（77 aa） Fragment：RESIDUES 2-78
Not recorded ZN ZINC ION × 30 W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 30 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；PEG8000, HEPES BUFFER, SODIUM CHLORIDE, CALCIUM CHLORIDE, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.80 Å R-free 0.226
1D3E CRYO-EM STRUCTURE OF HUMAN RHINOVIRUS 16 (HRV16) COMPLEXED WITH A TWO-DOMAIN FRAGMENT OF ITS CELLULAR RECEPTOR, INTERCELLULAR ADHESION MOLECULE-1 (D1D2-ICAM-1). IMPLICATIONS FOR VIRUS-RECEPTOR INTERACTIONS. ALPHA CARBONS ONLY Deposited 1999-09-29 Assembly 1 Insufficient information Heteromer；Protein × 300 PDB declaration: 300-MERIC（300） Consistent with protein count
Chain 1 573–852（280 aa）
Chain 2 78–329（252 aa）
Chain 3 330–567（238 aa）
Chain 4 1–68（68 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions HRV16 WAS INCUBATED WITH D1D2-ICAM-1 FOR 16 HOURS AT 34 DEGREES CELSIUS (307 KELVIN) USING A SIXTEEN-FOLD EXCESS OF D1D2-ICAM-1 FOR EACH OF THE SIXTY POSSIBLE BINDING SITES PER VIRION. AFTER INCUBATION, SAMPLES WERE PREPARED AS THIN LAYERS OF VITREOUS ICE AND MAINTAINED AT NEAR LIQUID NITROGEN TEMPERATURE IN THE ELECTRON MICROSCOPE WITH A GATAN 626 CRYOTRANSFER HOLDER
Resolution 28.00 Å
1D3E CRYO-EM STRUCTURE OF HUMAN RHINOVIRUS 16 (HRV16) COMPLEXED WITH A TWO-DOMAIN FRAGMENT OF ITS CELLULAR RECEPTOR, INTERCELLULAR ADHESION MOLECULE-1 (D1D2-ICAM-1). IMPLICATIONS FOR VIRUS-RECEPTOR INTERACTIONS. ALPHA CARBONS ONLY Deposited 1999-09-29 Assembly 2 Insufficient information Heteromer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain 1 573–852（280 aa）
Chain 2 78–329（252 aa）
Chain 3 330–567（238 aa）
Chain 4 1–68（68 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions HRV16 WAS INCUBATED WITH D1D2-ICAM-1 FOR 16 HOURS AT 34 DEGREES CELSIUS (307 KELVIN) USING A SIXTEEN-FOLD EXCESS OF D1D2-ICAM-1 FOR EACH OF THE SIXTY POSSIBLE BINDING SITES PER VIRION. AFTER INCUBATION, SAMPLES WERE PREPARED AS THIN LAYERS OF VITREOUS ICE AND MAINTAINED AT NEAR LIQUID NITROGEN TEMPERATURE IN THE ELECTRON MICROSCOPE WITH A GATAN 626 CRYOTRANSFER HOLDER
Resolution 28.00 Å
1D3E CRYO-EM STRUCTURE OF HUMAN RHINOVIRUS 16 (HRV16) COMPLEXED WITH A TWO-DOMAIN FRAGMENT OF ITS CELLULAR RECEPTOR, INTERCELLULAR ADHESION MOLECULE-1 (D1D2-ICAM-1). IMPLICATIONS FOR VIRUS-RECEPTOR INTERACTIONS. ALPHA CARBONS ONLY Deposited 1999-09-29 Assembly 3 Insufficient information Heteromer；Protein × 25 PDB declaration: 25-meric（25） Consistent with protein count
Chain 1 573–852（280 aa）
Chain 2 78–329（252 aa）
Chain 3 330–567（238 aa）
Chain 4 1–68（68 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions HRV16 WAS INCUBATED WITH D1D2-ICAM-1 FOR 16 HOURS AT 34 DEGREES CELSIUS (307 KELVIN) USING A SIXTEEN-FOLD EXCESS OF D1D2-ICAM-1 FOR EACH OF THE SIXTY POSSIBLE BINDING SITES PER VIRION. AFTER INCUBATION, SAMPLES WERE PREPARED AS THIN LAYERS OF VITREOUS ICE AND MAINTAINED AT NEAR LIQUID NITROGEN TEMPERATURE IN THE ELECTRON MICROSCOPE WITH A GATAN 626 CRYOTRANSFER HOLDER
Resolution 28.00 Å
1D3E CRYO-EM STRUCTURE OF HUMAN RHINOVIRUS 16 (HRV16) COMPLEXED WITH A TWO-DOMAIN FRAGMENT OF ITS CELLULAR RECEPTOR, INTERCELLULAR ADHESION MOLECULE-1 (D1D2-ICAM-1). IMPLICATIONS FOR VIRUS-RECEPTOR INTERACTIONS. ALPHA CARBONS ONLY Deposited 1999-09-29 Assembly 4 Insufficient information Heteromer；Protein × 30 PDB declaration: 30-meric（30） Consistent with protein count
Chain 1 573–852（280 aa）
Chain 2 78–329（252 aa）
Chain 3 330–567（238 aa）
Chain 4 1–68（68 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions HRV16 WAS INCUBATED WITH D1D2-ICAM-1 FOR 16 HOURS AT 34 DEGREES CELSIUS (307 KELVIN) USING A SIXTEEN-FOLD EXCESS OF D1D2-ICAM-1 FOR EACH OF THE SIXTY POSSIBLE BINDING SITES PER VIRION. AFTER INCUBATION, SAMPLES WERE PREPARED AS THIN LAYERS OF VITREOUS ICE AND MAINTAINED AT NEAR LIQUID NITROGEN TEMPERATURE IN THE ELECTRON MICROSCOPE WITH A GATAN 626 CRYOTRANSFER HOLDER
Resolution 28.00 Å
1D3E CRYO-EM STRUCTURE OF HUMAN RHINOVIRUS 16 (HRV16) COMPLEXED WITH A TWO-DOMAIN FRAGMENT OF ITS CELLULAR RECEPTOR, INTERCELLULAR ADHESION MOLECULE-1 (D1D2-ICAM-1). IMPLICATIONS FOR VIRUS-RECEPTOR INTERACTIONS. ALPHA CARBONS ONLY Deposited 1999-09-29 Assembly 5 Insufficient information Heteromer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain 1 573–852（280 aa）
Chain 2 78–329（252 aa）
Chain 3 330–567（238 aa）
Chain 4 1–68（68 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions HRV16 WAS INCUBATED WITH D1D2-ICAM-1 FOR 16 HOURS AT 34 DEGREES CELSIUS (307 KELVIN) USING A SIXTEEN-FOLD EXCESS OF D1D2-ICAM-1 FOR EACH OF THE SIXTY POSSIBLE BINDING SITES PER VIRION. AFTER INCUBATION, SAMPLES WERE PREPARED AS THIN LAYERS OF VITREOUS ICE AND MAINTAINED AT NEAR LIQUID NITROGEN TEMPERATURE IN THE ELECTRON MICROSCOPE WITH A GATAN 626 CRYOTRANSFER HOLDER
Resolution 28.00 Å
1NCR The structure of Rhinovirus 16 when complexed with pleconaril, an antiviral compound Deposited 2002-12-05 Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC（240） Consistent with protein count
Chain A 569–853（285 aa）
Chain B 70–330（261 aa）
Chain C 331–568（238 aa）
Chain D 2–69（68 aa）
Not recorded ZN ZINC ION × 60 W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 60 MYR MYRISTIC ACID × 60 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.70 Å R-free 0.247
1NCR The structure of Rhinovirus 16 when complexed with pleconaril, an antiviral compound Deposited 2002-12-05 Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric（4） Consistent with protein count
Chain A 569–853（285 aa）
Chain B 70–330（261 aa）
Chain C 331–568（238 aa）
Chain D 2–69（68 aa）
Not recorded ZN ZINC ION × 1 W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 1 MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.70 Å R-free 0.247
1NCR The structure of Rhinovirus 16 when complexed with pleconaril, an antiviral compound Deposited 2002-12-05 Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric（20） Consistent with protein count
Chain A 569–853（285 aa）
Chain B 70–330（261 aa）
Chain C 331–568（238 aa）
Chain D 2–69（68 aa）
Not recorded ZN ZINC ION × 5 W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 5 MYR MYRISTIC ACID × 5 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.70 Å R-free 0.247
1NCR The structure of Rhinovirus 16 when complexed with pleconaril, an antiviral compound Deposited 2002-12-05 Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric（24） Consistent with protein count
Chain A 569–853（285 aa）
Chain B 70–330（261 aa）
Chain C 331–568（238 aa）
Chain D 2–69（68 aa）
Not recorded ZN ZINC ION × 6 W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 6 MYR MYRISTIC ACID × 6 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.70 Å R-free 0.247
1NCR The structure of Rhinovirus 16 when complexed with pleconaril, an antiviral compound Deposited 2002-12-05 Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric（4） Consistent with protein count
Chain A 569–853（285 aa）
Chain B 70–330（261 aa）
Chain C 331–568（238 aa）
Chain D 2–69（68 aa）
Not recorded ZN ZINC ION × 1 W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 1 MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.70 Å R-free 0.247
1ND2 The structure of Rhinovirus 16 Deposited 2002-12-06 Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC（240） Consistent with protein count
Chain A 569–853（285 aa）
Chain B 70–330（261 aa）
Chain C 331–568（238 aa）
Chain D 2–69（68 aa）
Not recorded ZN ZINC ION × 60 MYR MYRISTIC ACID × 120 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.50 Å R-free 0.206
1ND2 The structure of Rhinovirus 16 Deposited 2002-12-06 Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric（4） Consistent with protein count
Chain A 569–853（285 aa）
Chain B 70–330（261 aa）
Chain C 331–568（238 aa）
Chain D 2–69（68 aa）
Not recorded ZN ZINC ION × 1 MYR MYRISTIC ACID × 2 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.50 Å R-free 0.206
1ND2 The structure of Rhinovirus 16 Deposited 2002-12-06 Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric（20） Consistent with protein count
Chain A 569–853（285 aa）
Chain B 70–330（261 aa）
Chain C 331–568（238 aa）
Chain D 2–69（68 aa）
Not recorded ZN ZINC ION × 5 MYR MYRISTIC ACID × 10 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.50 Å R-free 0.206
1ND2 The structure of Rhinovirus 16 Deposited 2002-12-06 Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric（24） Consistent with protein count
Chain A 569–853（285 aa）
Chain B 70–330（261 aa）
Chain C 331–568（238 aa）
Chain D 2–69（68 aa）
Not recorded ZN ZINC ION × 6 MYR MYRISTIC ACID × 12 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.50 Å R-free 0.206
1ND2 The structure of Rhinovirus 16 Deposited 2002-12-06 Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric（4） Consistent with protein count
Chain A 569–853（285 aa）
Chain B 70–330（261 aa）
Chain C 331–568（238 aa）
Chain D 2–69（68 aa）
Not recorded ZN ZINC ION × 1 MYR MYRISTIC ACID × 2 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.50 Å R-free 0.206
1ND3 The structure of HRV16, when complexed with pleconaril, an antiviral compound Deposited 2002-12-06 Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC（240） Consistent with protein count
Chain A 569–853（285 aa）
Chain B 70–330（261 aa）
Chain C 331–568（238 aa）
Chain D 2–69（68 aa）
Not recorded ZN ZINC ION × 60 W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 60 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.80 Å R-free 0.243
1ND3 The structure of HRV16, when complexed with pleconaril, an antiviral compound Deposited 2002-12-06 Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric（4） Consistent with protein count
Chain A 569–853（285 aa）
Chain B 70–330（261 aa）
Chain C 331–568（238 aa）
Chain D 2–69（68 aa）
Not recorded ZN ZINC ION × 1 W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.80 Å R-free 0.243
1ND3 The structure of HRV16, when complexed with pleconaril, an antiviral compound Deposited 2002-12-06 Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric（20） Consistent with protein count
Chain A 569–853（285 aa）
Chain B 70–330（261 aa）
Chain C 331–568（238 aa）
Chain D 2–69（68 aa）
Not recorded ZN ZINC ION × 5 W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 5 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.80 Å R-free 0.243
1ND3 The structure of HRV16, when complexed with pleconaril, an antiviral compound Deposited 2002-12-06 Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric（24） Consistent with protein count
Chain A 569–853（285 aa）
Chain B 70–330（261 aa）
Chain C 331–568（238 aa）
Chain D 2–69（68 aa）
Not recorded ZN ZINC ION × 6 W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 6 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.80 Å R-free 0.243
1ND3 The structure of HRV16, when complexed with pleconaril, an antiviral compound Deposited 2002-12-06 Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric（4） Consistent with protein count
Chain A 569–853（285 aa）
Chain B 70–330（261 aa）
Chain C 331–568（238 aa）
Chain D 2–69（68 aa）
Not recorded ZN ZINC ION × 1 W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.80 Å R-free 0.243
1QJU HUMAN RHINOVIRUS 16 COAT PROTEIN IN COMPLEX WITH ANTIVIRAL COMPOUND VP61209 Deposited 1999-07-05 Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC（240） Consistent with protein count
Chain 1 569–853（285 aa） Fragment：RESIDUES 569-853
Chain 2 70–330（261 aa） Fragment：RESIDUES 70-330
Chain 3 331–568（238 aa） Fragment：RESIDUES 331-568
Chain 4 2–69（68 aa） Fragment：RESIDUES 2-69
Not recorded ZN ZINC ION × 60 W01 2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[2N-METHYL-2H-TETRAZOL-5-YL]-PHENOL × 60 MYR MYRISTIC ACID × 60 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；VIRUS WAS CRYSTALLISED USING THE HANGING DROP METHOD. 5 MICROLITERS OF VIRUS SOLUTION IN 0.25M HEPES BUFFER (PH 7.5), WITH 0.25M NACL WAS MIXED WITH 5 MICROLITERS OF THE RESERVOIR SOLUTION, 0.5-1.5% PEG 8000.
Resolution 2.80 Å R-free 0.212
1QJU HUMAN RHINOVIRUS 16 COAT PROTEIN IN COMPLEX WITH ANTIVIRAL COMPOUND VP61209 Deposited 1999-07-05 Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric（4） Consistent with protein count
Chain 1 569–853（285 aa） Fragment：RESIDUES 569-853
Chain 2 70–330（261 aa） Fragment：RESIDUES 70-330
Chain 3 331–568（238 aa） Fragment：RESIDUES 331-568
Chain 4 2–69（68 aa） Fragment：RESIDUES 2-69
Not recorded ZN ZINC ION × 1 W01 2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[2N-METHYL-2H-TETRAZOL-5-YL]-PHENOL × 1 MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；VIRUS WAS CRYSTALLISED USING THE HANGING DROP METHOD. 5 MICROLITERS OF VIRUS SOLUTION IN 0.25M HEPES BUFFER (PH 7.5), WITH 0.25M NACL WAS MIXED WITH 5 MICROLITERS OF THE RESERVOIR SOLUTION, 0.5-1.5% PEG 8000.
Resolution 2.80 Å R-free 0.212
1QJU HUMAN RHINOVIRUS 16 COAT PROTEIN IN COMPLEX WITH ANTIVIRAL COMPOUND VP61209 Deposited 1999-07-05 Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric（20） Consistent with protein count
Chain 1 569–853（285 aa） Fragment：RESIDUES 569-853
Chain 2 70–330（261 aa） Fragment：RESIDUES 70-330
Chain 3 331–568（238 aa） Fragment：RESIDUES 331-568
Chain 4 2–69（68 aa） Fragment：RESIDUES 2-69
Not recorded ZN ZINC ION × 5 W01 2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[2N-METHYL-2H-TETRAZOL-5-YL]-PHENOL × 5 MYR MYRISTIC ACID × 5 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；VIRUS WAS CRYSTALLISED USING THE HANGING DROP METHOD. 5 MICROLITERS OF VIRUS SOLUTION IN 0.25M HEPES BUFFER (PH 7.5), WITH 0.25M NACL WAS MIXED WITH 5 MICROLITERS OF THE RESERVOIR SOLUTION, 0.5-1.5% PEG 8000.
Resolution 2.80 Å R-free 0.212
1QJU HUMAN RHINOVIRUS 16 COAT PROTEIN IN COMPLEX WITH ANTIVIRAL COMPOUND VP61209 Deposited 1999-07-05 Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric（24） Consistent with protein count
Chain 1 569–853（285 aa） Fragment：RESIDUES 569-853
Chain 2 70–330（261 aa） Fragment：RESIDUES 70-330
Chain 3 331–568（238 aa） Fragment：RESIDUES 331-568
Chain 4 2–69（68 aa） Fragment：RESIDUES 2-69
Not recorded ZN ZINC ION × 6 W01 2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[2N-METHYL-2H-TETRAZOL-5-YL]-PHENOL × 6 MYR MYRISTIC ACID × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；VIRUS WAS CRYSTALLISED USING THE HANGING DROP METHOD. 5 MICROLITERS OF VIRUS SOLUTION IN 0.25M HEPES BUFFER (PH 7.5), WITH 0.25M NACL WAS MIXED WITH 5 MICROLITERS OF THE RESERVOIR SOLUTION, 0.5-1.5% PEG 8000.
Resolution 2.80 Å R-free 0.212
1QJU HUMAN RHINOVIRUS 16 COAT PROTEIN IN COMPLEX WITH ANTIVIRAL COMPOUND VP61209 Deposited 1999-07-05 Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric（4） Consistent with protein count
Chain 1 569–853（285 aa） Fragment：RESIDUES 569-853
Chain 2 70–330（261 aa） Fragment：RESIDUES 70-330
Chain 3 331–568（238 aa） Fragment：RESIDUES 331-568
Chain 4 2–69（68 aa） Fragment：RESIDUES 2-69
Not recorded ZN ZINC ION × 1 W01 2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[2N-METHYL-2H-TETRAZOL-5-YL]-PHENOL × 1 MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；VIRUS WAS CRYSTALLISED USING THE HANGING DROP METHOD. 5 MICROLITERS OF VIRUS SOLUTION IN 0.25M HEPES BUFFER (PH 7.5), WITH 0.25M NACL WAS MIXED WITH 5 MICROLITERS OF THE RESERVOIR SOLUTION, 0.5-1.5% PEG 8000.
Resolution 2.80 Å R-free 0.212
1QJU HUMAN RHINOVIRUS 16 COAT PROTEIN IN COMPLEX WITH ANTIVIRAL COMPOUND VP61209 Deposited 1999-07-05 Assembly 6 Protein homooligomer Homooligomer；Protein × 120 PDB declaration: 120-meric（120） Consistent with protein count
Chain 1 569–853（285 aa） Fragment：RESIDUES 569-853
Chain 2 70–330（261 aa） Fragment：RESIDUES 70-330
Chain 3 331–568（238 aa） Fragment：RESIDUES 331-568
Chain 4 2–69（68 aa） Fragment：RESIDUES 2-69
Not recorded ZN ZINC ION × 30 W01 2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[2N-METHYL-2H-TETRAZOL-5-YL]-PHENOL × 30 MYR MYRISTIC ACID × 30 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；VIRUS WAS CRYSTALLISED USING THE HANGING DROP METHOD. 5 MICROLITERS OF VIRUS SOLUTION IN 0.25M HEPES BUFFER (PH 7.5), WITH 0.25M NACL WAS MIXED WITH 5 MICROLITERS OF THE RESERVOIR SOLUTION, 0.5-1.5% PEG 8000.
Resolution 2.80 Å R-free 0.212
1QJX HUMAN RHINOVIRUS 16 COAT PROTEIN IN COMPLEX WITH ANTIVIRAL COMPOUND WIN68934 Deposited 1999-07-06 Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC（240） Consistent with protein count
Chain 1 569–853（285 aa） Fragment：RESIDUES 569-853
Chain 2 70–330（261 aa） Fragment：RESIDUES 70-330
Chain 3 331–568（238 aa） Fragment：RESIDUES 331-568
Chain 4 2–69（68 aa） Fragment：RESIDUES 2-69
Not recorded ZN ZINC ION × 60 W02 2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[4-METHYL-2H-TETRAZOL-2-YL]-PHENOL × 60 MYR MYRISTIC ACID × 60 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；VIRUS WAS CRYSTALLISED USING THE HANGING DROP METHOD. 5 MICROLITERS OF VIRUS SOLUTION IN 0.25M HEPES BUFFER (PH 7.5), WITH 0.25M NACL WAS MIXED WITH 5 MICROLITERS OF THE RESERVOIR SOLUTION, 0.5-1.5% PEG 8000.
Resolution 2.80 Å R-free 0.235
1QJX HUMAN RHINOVIRUS 16 COAT PROTEIN IN COMPLEX WITH ANTIVIRAL COMPOUND WIN68934 Deposited 1999-07-06 Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric（4） Consistent with protein count
Chain 1 569–853（285 aa） Fragment：RESIDUES 569-853
Chain 2 70–330（261 aa） Fragment：RESIDUES 70-330
Chain 3 331–568（238 aa） Fragment：RESIDUES 331-568
Chain 4 2–69（68 aa） Fragment：RESIDUES 2-69
Not recorded ZN ZINC ION × 1 W02 2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[4-METHYL-2H-TETRAZOL-2-YL]-PHENOL × 1 MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；VIRUS WAS CRYSTALLISED USING THE HANGING DROP METHOD. 5 MICROLITERS OF VIRUS SOLUTION IN 0.25M HEPES BUFFER (PH 7.5), WITH 0.25M NACL WAS MIXED WITH 5 MICROLITERS OF THE RESERVOIR SOLUTION, 0.5-1.5% PEG 8000.
Resolution 2.80 Å R-free 0.235
1QJX HUMAN RHINOVIRUS 16 COAT PROTEIN IN COMPLEX WITH ANTIVIRAL COMPOUND WIN68934 Deposited 1999-07-06 Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric（20） Consistent with protein count
Chain 1 569–853（285 aa） Fragment：RESIDUES 569-853
Chain 2 70–330（261 aa） Fragment：RESIDUES 70-330
Chain 3 331–568（238 aa） Fragment：RESIDUES 331-568
Chain 4 2–69（68 aa） Fragment：RESIDUES 2-69
Not recorded ZN ZINC ION × 5 W02 2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[4-METHYL-2H-TETRAZOL-2-YL]-PHENOL × 5 MYR MYRISTIC ACID × 5 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；VIRUS WAS CRYSTALLISED USING THE HANGING DROP METHOD. 5 MICROLITERS OF VIRUS SOLUTION IN 0.25M HEPES BUFFER (PH 7.5), WITH 0.25M NACL WAS MIXED WITH 5 MICROLITERS OF THE RESERVOIR SOLUTION, 0.5-1.5% PEG 8000.
Resolution 2.80 Å R-free 0.235
1QJX HUMAN RHINOVIRUS 16 COAT PROTEIN IN COMPLEX WITH ANTIVIRAL COMPOUND WIN68934 Deposited 1999-07-06 Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric（24） Consistent with protein count
Chain 1 569–853（285 aa） Fragment：RESIDUES 569-853
Chain 2 70–330（261 aa） Fragment：RESIDUES 70-330
Chain 3 331–568（238 aa） Fragment：RESIDUES 331-568
Chain 4 2–69（68 aa） Fragment：RESIDUES 2-69
Not recorded ZN ZINC ION × 6 W02 2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[4-METHYL-2H-TETRAZOL-2-YL]-PHENOL × 6 MYR MYRISTIC ACID × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；VIRUS WAS CRYSTALLISED USING THE HANGING DROP METHOD. 5 MICROLITERS OF VIRUS SOLUTION IN 0.25M HEPES BUFFER (PH 7.5), WITH 0.25M NACL WAS MIXED WITH 5 MICROLITERS OF THE RESERVOIR SOLUTION, 0.5-1.5% PEG 8000.
Resolution 2.80 Å R-free 0.235
1QJX HUMAN RHINOVIRUS 16 COAT PROTEIN IN COMPLEX WITH ANTIVIRAL COMPOUND WIN68934 Deposited 1999-07-06 Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric（4） Consistent with protein count
Chain 1 569–853（285 aa） Fragment：RESIDUES 569-853
Chain 2 70–330（261 aa） Fragment：RESIDUES 70-330
Chain 3 331–568（238 aa） Fragment：RESIDUES 331-568
Chain 4 2–69（68 aa） Fragment：RESIDUES 2-69
Not recorded ZN ZINC ION × 1 W02 2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[4-METHYL-2H-TETRAZOL-2-YL]-PHENOL × 1 MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；VIRUS WAS CRYSTALLISED USING THE HANGING DROP METHOD. 5 MICROLITERS OF VIRUS SOLUTION IN 0.25M HEPES BUFFER (PH 7.5), WITH 0.25M NACL WAS MIXED WITH 5 MICROLITERS OF THE RESERVOIR SOLUTION, 0.5-1.5% PEG 8000.
Resolution 2.80 Å R-free 0.235
1QJX HUMAN RHINOVIRUS 16 COAT PROTEIN IN COMPLEX WITH ANTIVIRAL COMPOUND WIN68934 Deposited 1999-07-06 Assembly 6 Protein homooligomer Homooligomer；Protein × 120 PDB declaration: 120-meric（120） Consistent with protein count
Chain 1 569–853（285 aa） Fragment：RESIDUES 569-853
Chain 2 70–330（261 aa） Fragment：RESIDUES 70-330
Chain 3 331–568（238 aa） Fragment：RESIDUES 331-568
Chain 4 2–69（68 aa） Fragment：RESIDUES 2-69
Not recorded ZN ZINC ION × 30 W02 2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[4-METHYL-2H-TETRAZOL-2-YL]-PHENOL × 30 MYR MYRISTIC ACID × 30 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；VIRUS WAS CRYSTALLISED USING THE HANGING DROP METHOD. 5 MICROLITERS OF VIRUS SOLUTION IN 0.25M HEPES BUFFER (PH 7.5), WITH 0.25M NACL WAS MIXED WITH 5 MICROLITERS OF THE RESERVOIR SOLUTION, 0.5-1.5% PEG 8000.
Resolution 2.80 Å R-free 0.235
1QJY HUMAN RHINOVIRUS 16 COAT PROTEIN IN COMPLEX WITH ANTIVIRAL COMPOUND VP65099 Deposited 1999-07-06 Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC（240） Consistent with protein count
Chain 1 569–853（285 aa） Fragment：RESIDUES 569-853
Chain 2 70–330（261 aa） Fragment：RESIDUES 70-330
Chain 3 331–568（238 aa） Fragment：RESIDUES 331-568
Chain 4 2–69（68 aa） Fragment：RESIDUES 2-69
Not recorded ZN ZINC ION × 60 W03 2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[2-METHYL-4-ISOXAZOLYL]-PHENOL × 60 MYR MYRISTIC ACID × 60 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；VIRUS WAS CRYSTALLISED USING THE HANGING DROP METHOD. 5 MICROLITERS OF VIRUS SOLUTION IN 0.25M HEPES BUFFER (PH 7.5), WITH 0.25M NACL WAS MIXED WITH 5 MICROLITERS OF THE RESERVOIR SOLUTION, 0.5-1.5% PEG 8000.
Resolution 2.80 Å R-free 0.233
1QJY HUMAN RHINOVIRUS 16 COAT PROTEIN IN COMPLEX WITH ANTIVIRAL COMPOUND VP65099 Deposited 1999-07-06 Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric（4） Consistent with protein count
Chain 1 569–853（285 aa） Fragment：RESIDUES 569-853
Chain 2 70–330（261 aa） Fragment：RESIDUES 70-330
Chain 3 331–568（238 aa） Fragment：RESIDUES 331-568
Chain 4 2–69（68 aa） Fragment：RESIDUES 2-69
Not recorded ZN ZINC ION × 1 W03 2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[2-METHYL-4-ISOXAZOLYL]-PHENOL × 1 MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；VIRUS WAS CRYSTALLISED USING THE HANGING DROP METHOD. 5 MICROLITERS OF VIRUS SOLUTION IN 0.25M HEPES BUFFER (PH 7.5), WITH 0.25M NACL WAS MIXED WITH 5 MICROLITERS OF THE RESERVOIR SOLUTION, 0.5-1.5% PEG 8000.
Resolution 2.80 Å R-free 0.233
1QJY HUMAN RHINOVIRUS 16 COAT PROTEIN IN COMPLEX WITH ANTIVIRAL COMPOUND VP65099 Deposited 1999-07-06 Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric（20） Consistent with protein count
Chain 1 569–853（285 aa） Fragment：RESIDUES 569-853
Chain 2 70–330（261 aa） Fragment：RESIDUES 70-330
Chain 3 331–568（238 aa） Fragment：RESIDUES 331-568
Chain 4 2–69（68 aa） Fragment：RESIDUES 2-69
Not recorded ZN ZINC ION × 5 W03 2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[2-METHYL-4-ISOXAZOLYL]-PHENOL × 5 MYR MYRISTIC ACID × 5 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；VIRUS WAS CRYSTALLISED USING THE HANGING DROP METHOD. 5 MICROLITERS OF VIRUS SOLUTION IN 0.25M HEPES BUFFER (PH 7.5), WITH 0.25M NACL WAS MIXED WITH 5 MICROLITERS OF THE RESERVOIR SOLUTION, 0.5-1.5% PEG 8000.
Resolution 2.80 Å R-free 0.233
1QJY HUMAN RHINOVIRUS 16 COAT PROTEIN IN COMPLEX WITH ANTIVIRAL COMPOUND VP65099 Deposited 1999-07-06 Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric（24） Consistent with protein count
Chain 1 569–853（285 aa） Fragment：RESIDUES 569-853
Chain 2 70–330（261 aa） Fragment：RESIDUES 70-330
Chain 3 331–568（238 aa） Fragment：RESIDUES 331-568
Chain 4 2–69（68 aa） Fragment：RESIDUES 2-69
Not recorded ZN ZINC ION × 6 W03 2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[2-METHYL-4-ISOXAZOLYL]-PHENOL × 6 MYR MYRISTIC ACID × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；VIRUS WAS CRYSTALLISED USING THE HANGING DROP METHOD. 5 MICROLITERS OF VIRUS SOLUTION IN 0.25M HEPES BUFFER (PH 7.5), WITH 0.25M NACL WAS MIXED WITH 5 MICROLITERS OF THE RESERVOIR SOLUTION, 0.5-1.5% PEG 8000.
Resolution 2.80 Å R-free 0.233
1QJY HUMAN RHINOVIRUS 16 COAT PROTEIN IN COMPLEX WITH ANTIVIRAL COMPOUND VP65099 Deposited 1999-07-06 Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric（4） Consistent with protein count
Chain 1 569–853（285 aa） Fragment：RESIDUES 569-853
Chain 2 70–330（261 aa） Fragment：RESIDUES 70-330
Chain 3 331–568（238 aa） Fragment：RESIDUES 331-568
Chain 4 2–69（68 aa） Fragment：RESIDUES 2-69
Not recorded ZN ZINC ION × 1 W03 2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[2-METHYL-4-ISOXAZOLYL]-PHENOL × 1 MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；VIRUS WAS CRYSTALLISED USING THE HANGING DROP METHOD. 5 MICROLITERS OF VIRUS SOLUTION IN 0.25M HEPES BUFFER (PH 7.5), WITH 0.25M NACL WAS MIXED WITH 5 MICROLITERS OF THE RESERVOIR SOLUTION, 0.5-1.5% PEG 8000.
Resolution 2.80 Å R-free 0.233
1QJY HUMAN RHINOVIRUS 16 COAT PROTEIN IN COMPLEX WITH ANTIVIRAL COMPOUND VP65099 Deposited 1999-07-06 Assembly 6 Protein homooligomer Homooligomer；Protein × 120 PDB declaration: 120-meric（120） Consistent with protein count
Chain 1 569–853（285 aa） Fragment：RESIDUES 569-853
Chain 2 70–330（261 aa） Fragment：RESIDUES 70-330
Chain 3 331–568（238 aa） Fragment：RESIDUES 331-568
Chain 4 2–69（68 aa） Fragment：RESIDUES 2-69
Not recorded ZN ZINC ION × 30 W03 2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[2-METHYL-4-ISOXAZOLYL]-PHENOL × 30 MYR MYRISTIC ACID × 30 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；VIRUS WAS CRYSTALLISED USING THE HANGING DROP METHOD. 5 MICROLITERS OF VIRUS SOLUTION IN 0.25M HEPES BUFFER (PH 7.5), WITH 0.25M NACL WAS MIXED WITH 5 MICROLITERS OF THE RESERVOIR SOLUTION, 0.5-1.5% PEG 8000.
Resolution 2.80 Å R-free 0.233
1TP7 Crystal Structure of the RNA-dependent RNA Polymerase from Human Rhinovirus 16 Deposited 2004-06-15 Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count
Chain A 1694–2153（460 aa） Fragment：RNA-directed RNA Polymerase (residues 1694-2153)
Non-standard monomer：Yes (specific site not provided by mmCIF) SO4 SULFATE ION × 1 DMX 3-[BENZYL(DIMETHYL)AMMONIO]PROPANE-1-SULFONATE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.6；295 K；PEG 4000, ammonium sulfate, dimethylbenzylammonium propane sulfonate, sodium citrate, glycerol, dithiothreitol, pH 5.6, VAPOR DIFFUSION, SITTING DROP, temperature 295.0K
Resolution 2.40 Å R-free 0.292
1TP7 Crystal Structure of the RNA-dependent RNA Polymerase from Human Rhinovirus 16 Deposited 2004-06-15 Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count
Chain B 1694–2153（460 aa） Fragment：RNA-directed RNA Polymerase (residues 1694-2153)
Non-standard monomer：Yes (specific site not provided by mmCIF) SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.6；295 K；PEG 4000, ammonium sulfate, dimethylbenzylammonium propane sulfonate, sodium citrate, glycerol, dithiothreitol, pH 5.6, VAPOR DIFFUSION, SITTING DROP, temperature 295.0K
Resolution 2.40 Å R-free 0.292
1TP7 Crystal Structure of the RNA-dependent RNA Polymerase from Human Rhinovirus 16 Deposited 2004-06-15 Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count
Chain C 1694–2153（460 aa） Fragment：RNA-directed RNA Polymerase (residues 1694-2153)
Non-standard monomer：Yes (specific site not provided by mmCIF) SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.6；295 K；PEG 4000, ammonium sulfate, dimethylbenzylammonium propane sulfonate, sodium citrate, glycerol, dithiothreitol, pH 5.6, VAPOR DIFFUSION, SITTING DROP, temperature 295.0K
Resolution 2.40 Å R-free 0.292
1TP7 Crystal Structure of the RNA-dependent RNA Polymerase from Human Rhinovirus 16 Deposited 2004-06-15 Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count
Chain D 1694–2153（460 aa） Fragment：RNA-directed RNA Polymerase (residues 1694-2153)
Non-standard monomer：Yes (specific site not provided by mmCIF) SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.6；295 K；PEG 4000, ammonium sulfate, dimethylbenzylammonium propane sulfonate, sodium citrate, glycerol, dithiothreitol, pH 5.6, VAPOR DIFFUSION, SITTING DROP, temperature 295.0K
Resolution 2.40 Å R-free 0.292
1XR7 Crystal structure of RNA-dependent RNA Polymerase 3D from human rhinovirus serotype 16 Deposited 2004-10-13 Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count
Chain A 1694–2153（460 aa） Fragment：RNA-DIRECTED RNA POLYMERASE
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.6；286 K；ammonium sulfate, citrate, AMPPNP, MgCl2 or MnCl2, pH 5.60, VAPOR DIFFUSION, HANGING DROP, temperature 286K
Resolution 2.30 Å R-free 0.297
1XR7 Crystal structure of RNA-dependent RNA Polymerase 3D from human rhinovirus serotype 16 Deposited 2004-10-13 Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count
Chain B 1694–2153（460 aa） Fragment：RNA-DIRECTED RNA POLYMERASE
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.6；286 K；ammonium sulfate, citrate, AMPPNP, MgCl2 or MnCl2, pH 5.60, VAPOR DIFFUSION, HANGING DROP, temperature 286K
Resolution 2.30 Å R-free 0.297
4K50 Rhinovirus 16 polymerase elongation complex (r1_form) Deposited 2013-04-12 Assembly 1 Protein–RNA Monomer；Protein × 1 PDB declaration: trimeric（3） Consistent with all polymers
Chain A 1694–2153（460 aa） Fragment：unp residues 1694-2153
Not recorded GOL GLYCEROL × 1 ACT ACETATE ION × 6 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；289 K；0.16 M ammonium sulfate, 0.08 M sodium acetate, pH 4.6, 20% (w/v) PEG 4000, and 20% (v/v) glycerol and directly frozen , VAPOR DIFFUSION, SITTING DROP, temperature 289K
Resolution 2.93 Å R-free 0.247
4K50 Rhinovirus 16 polymerase elongation complex (r1_form) Deposited 2013-04-12 Assembly 2 Protein–RNA Monomer；Protein × 1 PDB declaration: trimeric（3） Consistent with all polymers
Chain E 1694–2153（460 aa） Fragment：unp residues 1694-2153
Not recorded ACT ACETATE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；289 K；0.16 M ammonium sulfate, 0.08 M sodium acetate, pH 4.6, 20% (w/v) PEG 4000, and 20% (v/v) glycerol and directly frozen , VAPOR DIFFUSION, SITTING DROP, temperature 289K
Resolution 2.93 Å R-free 0.247
4K50 Rhinovirus 16 polymerase elongation complex (r1_form) Deposited 2013-04-12 Assembly 3 Protein–RNA Monomer；Protein × 1 PDB declaration: trimeric（3） Consistent with all polymers
Chain I 1694–2153（460 aa） Fragment：unp residues 1694-2153
Not recorded GOL GLYCEROL × 2 ACT ACETATE ION × 7 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；289 K；0.16 M ammonium sulfate, 0.08 M sodium acetate, pH 4.6, 20% (w/v) PEG 4000, and 20% (v/v) glycerol and directly frozen , VAPOR DIFFUSION, SITTING DROP, temperature 289K
Resolution 2.93 Å R-free 0.247
4K50 Rhinovirus 16 polymerase elongation complex (r1_form) Deposited 2013-04-12 Assembly 4 Protein–RNA Monomer；Protein × 1 PDB declaration: trimeric（3） Consistent with all polymers
Chain M 1694–2153（460 aa） Fragment：unp residues 1694-2153
Not recorded ACT ACETATE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；289 K；0.16 M ammonium sulfate, 0.08 M sodium acetate, pH 4.6, 20% (w/v) PEG 4000, and 20% (v/v) glycerol and directly frozen , VAPOR DIFFUSION, SITTING DROP, temperature 289K
Resolution 2.93 Å R-free 0.247

This page presents structural evidence recorded in PDB/mmCIF.“No recorded non-water small molecule” does not prove that the experimental sample was ligand-free; experimental conditions belong to the PDB experiment, while ligands and copy counts are shown for each biological assembly.